Handelsavisen
prelaunch
Companies Healthcare 4576.T
45
4576.T Tokyo Stock Exchange Biotechnology & Medical Research

4576.T

¥70,00
Open in Charts → Attach watcher ⌖
JPY
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
4,0B JPY
P/E
EV / Rev
Div yield
0,00 %
Op margin
-159,9 %
ROE
-44,0 %
Net margin
-163,1 %
Debt / equity
0,42
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-44,0 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 4576.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 4576.T. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research activities.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company has a strong liquidity position, with cash and equivalents amounting to ¥170,979,000,000, significantly exceeding its total liabilities of ¥73,401,200,000. The current ratio of 9.91 indicates a robust ability to meet short-term obligations. However, the company is currently unprofitable, with a net loss of ¥632,086,000 and an operating loss of ¥619,870,000. The return on equity (ROE) is -0.4403, and the return on assets (ROA) is -0.2914, both significantly below industry norms.

    The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.42, suggesting a low reliance on debt financing. The price-to-book ratio of 3.02 and the price-to-tangible-book ratio of 3.02 indicate that the market is valuing the company's intangible assets at a premium. Despite this, the company's negative operating and free cash flows suggest ongoing financial strain, with operating cash flow at -¥493,795,000 and free cash flow at -¥587,312,000.

    The company's revenue is concentrated in a single business segment, as disclosed in the financial snapshot, with no specific geographic breakdown provided. This lack of diversification could pose a risk if the company's primary market experiences a downturn. The company's growth trajectory is currently negative, with a net loss and declining profitability. Analysts have reported a last actual EPS of -13.19 JPY and a last actual revenue of ¥387,620,000, indicating a challenging operating environment.

    The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. However, the negative operating and free cash flows suggest potential future liquidity constraints if the company's financial performance does not improve. The company has not issued any recent events or filings that would indicate significant changes in its operational or financial status.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 9.91.
    • The company is currently unprofitable with a net loss of ¥632,086,000.
    • The company's capital structure is conservative with a debt-to-equity ratio of 0.42.
    • The company's revenue is concentrated in a single business segment.
    • The company's growth trajectory is negative with declining profitability.
    • The company has low liquidity and dilution risks.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    ¥70,00
    Market cap
    ¥4.33B
    Enterprise value
    ¥3.23B
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    3.0x
    P / Tangible book
    3.0x
    Tangible book
    ¥1.44B
    Net cash
    ¥1.10B
    Current ratio
    9.9
    Debt / equity
    0.4
    ROA
    -29.1%
    ROE
    -44.0%
    Cash conversion
    78.0%
    CapEx / revenue
    -0.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-159,9 %Above median
    Net Margin-163,1 %Above median
    ROE-44,0 %Below median
    Capex / Rev-0,7 %Above P75
    D/E0,42Bottom quartile
    Cash Conv0,78Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • 4576.T Market data — financials · 2026-05-26
    • D.Western Therapeutics Institute Inc Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    4576.TCanonical
    Tokyo Stock Exchange · JPY

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage